Compare Bristol-Myers Squibb Co (BMY) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs M&T Bank Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B), while M&T Bank Corporation trades at $251.93 (market cap $36.42B). The key difference: Bristol-Myers Squibb Co is far larger — about 3.6× M&T Bank Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | MTB | |
|---|---|---|
Market Cap | $129.94B | $36.42B |
Sector | Health | Financials |
52-Week High | $65.89 | $254.04 |
52-Week Low | $42.60 | $178.63 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
M&T Bank (MTB) trades at $253.46, up 0.93% today, near its consensus price target of $255.92. The stock shows bullish technical momentum, with recent earnings consistently beating estimates, including Q2 2026 EPS of $5.35 versus $4.66 expected. Revenue growth is steady, with 2025 revenue at $9.63 billion and net income margin improving to 29.59%. The company maintains a solid dividend, paying $1.50 in H1 2026.
Outlook remains positive supported by strong fundamentals and analyst consensus, though risks include macroeconomic sensitivity and elevated investing cash outflows. The stock presents a value opportunity with a P/E of 13.35 and bullish institutional sentiment, but investors should monitor interest rate impacts and loan growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
